Companies TENAX THERAPEUTICS, INC.
TENAX THERAPEUTICS (TENX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me TENAX THERAPEUTICS, INC.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $644,770FY2023
- $7,403,591FY2024
- $8,079,633FY2025
CEO total pay was $8,079,633 in fiscal 2025, up from $7,403,591 in fiscal 2024.
FY2025: salary $563,734 · bonus $0 · stock awards $0 · option awards $7,266,000
Order TENX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Christopher Giordano | $563,734 | $0 | $0 | $7,266,000 | $204,375 | $0 | $45,524 | $8,079,633 |
| President and Chief Executive Officer | ||||||||
| Stuart Rich | 322,724 | 0 | 0 | 3,242,750 | 157,500 | 0 | 9,993 | 3,732,967 |
| Chief Medical Officer | ||||||||
| Thomas McGauley | 0 | 0 | 0 | 0 | 0 | 0 | 475,498 | 475,498 |
| Interim Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Christopher Giordano | $8,079,633 | $7,403,591 | $644,770 | ↑ +676,042 |
| Stuart Rich | 3,732,967 | 3,138,044 | 481,223 | ↑ +594,923 |
| Thomas McGauley | 475,498 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Compensation is provided through a mix of base salary, annual cash bonus based on achievement of predetermined operational goals, and long-term equity compensation in the form of options.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Anderson Pay Advisors |
| Clawback policy | true |
| Anti-hedging | false |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Stuart Rich | Option | 625,000 | 5.89 | — |
| Christopher Giordano | Option | 1,400,000 | 5.89 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Gerald T. ProehlIndependent · Board Chair · Nominating/Governance · Compensation | $88,500 | $0 | $395,200 | — | $0 | $483,700 |
| Robyn M. HunterIndependent · Audit · Compensation | 65,000 | 0 | 395,200 | — | 0 | 460,200 |
| June AlmenoffIndependent · Nominating/Governance · Audit | 59,500 | 0 | 395,200 | — | 0 | 454,700 |
| Michael DavidsonIndependent · Audit · Compensation | 57,500 | 0 | 395,200 | — | 0 | 452,700 |
| Declan DooganIndependent · Nominating/Governance | 48,500 | 0 | 395,200 | — | 0 | 443,700 |
| Stuart RichEmployee director | — | — | — | — | — | 0 |
| Christopher T. GiordanoEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 7,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $319,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $319,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names TENAX THERAPEUTICS as a peer
Companies that benchmark against TENX
No companies currently name TENX as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TENAX THERAPEUTICS, INC. | 2025 | Christopher Giordano | $563,734 | $0 | $7,266,000 | $204,375 | $8,079,633 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-11 | 2,435,043 | 30,284 | 20,722 | 98.77% | Passed |
| 2022 | 2022-06-09 | 13,901,272 | 1,123,419 | 120,754 | 91.79% | Passed |
| 2019 | 2019-06-13 | 3,242,063 | 386,611 | 15 | 89.35% | Passed |
| 2017 | 2017-06-14 | 3,958,457 | 232,710 | 66,218 | 94.45% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-11 | 98.77%a |
| 2022 | 2022-06-09 | 91.79%b |
| 2019 | 2019-06-13 | 89.35%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote against this proposal and broker non-votes will have no effect on the outcome of this Proposal 4.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (16 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Christopher Giordano. DEF 14A, filed 2026-04-22. Section “Executive Compensation”. As printed: 8,079,633. View filing ↗
- Section 01, Stuart Rich. DEF 14A, filed 2026-04-22. Section “Executive Compensation”. As printed: 3,732,967. View filing ↗
- Section 01, Thomas McGauley. DEF 14A, filed 2026-04-22. Section “Executive Compensation”. As printed: 475,498. View filing ↗
- Section 08, Gerald T. Proehl. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 483,700. View filing ↗
- Section 08, Robyn M. Hunter. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 460,200. View filing ↗
- Section 08, June Almenoff. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 454,700. View filing ↗
- Section 08, Michael Davidson. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 452,700. View filing ↗
- Section 08, Declan Doogan. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 443,700. View filing ↗
- Section 08, Stuart Rich. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Christopher T. Giordano. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-17. Item 5.07 · say-on-pay result. As reported: 98.77% (votes for as printed: 2,435,043). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-06-10. Item 5.07 · say-on-pay result. As reported: 91.79% (votes for as printed: 13,901,272). View filing ↗
- Section 06, 2019 vote. Form 8-K, filed 2019-06-14. Item 5.07 · say-on-pay result. As reported: 89.35% (votes for as printed: 3,242,063). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 319,000 + equity 0 + all other 0 = 319,000, summed across the director compensation table rows.
- TENAX THERAPEUTICS, INC. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in TENAX THERAPEUTICS, INC.'s own proxy. As printed: 8,079,633. View filing ↗